Sanaz Behtaj1,2,3, Andreas Öchsner4, Yuri G Anissimov2,5,6, Maksym Rybachuk7,8. 1. School of Engineering and Built Environment, Griffith University, Engineering Drive, Southport, QLD, 4222, Australia. 2. Queensland Micro- and Nanotechnology Centre, Griffith University, West Creek Road, Nathan, QLD, 4111, Australia. 3. Department of Cell and Molecular Biology, Cell Science Research Centre, Royan Institute for Biotechnology, Isfahan, Iran. 4. Faculty of Mechanical Engineering, Esslingen University of Applied Sciences, Kanalstrasse 33, 73728, Esslingen, Germany. 5. School of Environment and Science, Griffith University, Parklands Drive, Southport, QLD, 4222, Australia. 6. Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, 119146, Russia. 7. Queensland Micro- and Nanotechnology Centre, Griffith University, West Creek Road, Nathan, QLD, 4111, Australia. m.rybachuk@griffith.edu.au. 8. School of Engineering and Built Environment, Griffith University, 170 Kessels Road, Nathan, QLD, 4111, Australia. m.rybachuk@griffith.edu.au.
Abstract
BACKGROUND: Glaucoma, a characteristic type of optic nerve degeneration in the posterior pole of the eye, is a common cause of irreversible vision loss and the second leading cause of blindness worldwide. As an optic neuropathy, glaucoma is identified by increasing degeneration of retinal ganglion cells (RGCs), with consequential vision loss. Current treatments only postpone the development of retinal degeneration, and there are as yet no treatments available for this disability. Recent studies have shown that replacing lost or damaged RGCs with healthy RGCs or RGC precursors, supported by appropriately designed bio-material scaffolds, could facilitate the development and enhancement of connections to ganglion cells and optic nerve axons. The consequence may be an improved retinal regeneration. This technique could also offer the possibility for retinal regeneration in treating other forms of optic nerve ailments through RGC replacement. METHODS: In this brief review, we describe the innovations and recent developments in retinal regenerative medicine such as retinal organoids and gene therapy which are specific to glaucoma treatment and focus on the selection of appropriate bio-engineering principles, biomaterials and cell therapies that are presently employed in this growing research area. RESULTS: Identification of optimal sources of cells, improving cell survival, functional integration upon transplantation, and developing techniques to deliver cells into the retinal space without provoking immune responses are the main challenges in retinal cell replacement therapies. CONCLUSION: The restoration of visual function in glaucoma patients by the RGC replacement therapies requires appropriate protocols and biotechnology methods. Tissue-engineered scaffolds, the generation of retinal organoids, and gene therapy may help to overcome some of the challenges in the generation of clinically safe RGCs.
BACKGROUND:Glaucoma, a characteristic type of optic nerve degeneration in the posterior pole of the eye, is a common cause of irreversible vision loss and the second leading cause of blindness worldwide. As an optic neuropathy, glaucoma is identified by increasing degeneration of retinal ganglion cells (RGCs), with consequential vision loss. Current treatments only postpone the development of retinal degeneration, and there are as yet no treatments available for this disability. Recent studies have shown that replacing lost or damaged RGCs with healthy RGCs or RGC precursors, supported by appropriately designed bio-material scaffolds, could facilitate the development and enhancement of connections to ganglion cells and optic nerve axons. The consequence may be an improved retinal regeneration. This technique could also offer the possibility for retinal regeneration in treating other forms of optic nerve ailments through RGC replacement. METHODS: In this brief review, we describe the innovations and recent developments in retinal regenerative medicine such as retinal organoids and gene therapy which are specific to glaucoma treatment and focus on the selection of appropriate bio-engineering principles, biomaterials and cell therapies that are presently employed in this growing research area. RESULTS: Identification of optimal sources of cells, improving cell survival, functional integration upon transplantation, and developing techniques to deliver cells into the retinal space without provoking immune responses are the main challenges in retinal cell replacement therapies. CONCLUSION: The restoration of visual function in glaucomapatients by the RGC replacement therapies requires appropriate protocols and biotechnology methods. Tissue-engineered scaffolds, the generation of retinal organoids, and gene therapy may help to overcome some of the challenges in the generation of clinically safe RGCs.
Authors: Luca Della Santina; Denise M Inman; Caroline B Lupien; Philip J Horner; Rachel O L Wong Journal: J Neurosci Date: 2013-10-30 Impact factor: 6.167
Authors: Marcus Karlstetter; Rebecca Scholz; Matt Rutar; Wai T Wong; Jan M Provis; Thomas Langmann Journal: Prog Retin Eye Res Date: 2014-12-02 Impact factor: 21.198
Authors: Karl E Kador; Shawn P Grogan; Erik W Dorthé; Praseeda Venugopalan; Monisha F Malek; Jeffrey L Goldberg; Darryl D D'lima Journal: Tissue Eng Part A Date: 2016-01-27 Impact factor: 3.845
Authors: Lauren A Laboissonniere; Jillian J Goetz; Gregory M Martin; Ran Bi; Terry J S Lund; Laura Ellson; Madison R Lynch; Bailey Mooney; Hannah Wickham; Peng Liu; Gregory W Schwartz; Jeffrey M Trimarchi Journal: Sci Rep Date: 2019-10-31 Impact factor: 4.379
Authors: Nahla Jemni-Damer; Atocha Guedan-Duran; María Fuentes-Andion; Nora Serrano-Bengoechea; Nuria Alfageme-Lopez; Félix Armada-Maresca; Gustavo V Guinea; José Perez-Rigueiro; Francisco Rojo; Daniel Gonzalez-Nieto; David L Kaplan; Fivos Panetsos Journal: Front Bioeng Biotechnol Date: 2020-12-10